The company granted stock options to purchase an aggregate of 208,350 shares of Nurix common stock and restricted stock unit awards (RSUs) representing an aggregate of 272,850 shares of Nurix common ...
Eran Ovadya, Chief Financial Officer of NurExone stated, "The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback